Table 1.
Patient characteristics.
| Patients without TA-TMA (n = 57) | Patients with TA-TMA (n = 10) | P-value | |
|---|---|---|---|
| Age, years (median; IQR) | 7.1 (2.5–11.8) | 9.4 (6.7–14.3) | 0.07 |
| Male recipient sex | 31 (54.4) | 6 (60) | 1 |
| Indication of transplantation | |||
| Malignancy | 31 (54.39) | 6 (60) | |
| Bone marrow failure | 16 (28.1) | 3 (30) | 0.84 |
| Other (immune deficiency or metabolic disease) | 10 (17.5) | 1 (10) | |
| Recent transplantation | |||
| 0 | 53 (93) | 10 (100) | 1 |
| 1 | 4 (7) | 0 | |
| Donor type | |||
| Related identical or haploidentical | 21 (36.8) | 2 (20) | 0.47 |
| Unrelated | 36 (63.2) | 8 (80) | |
| Stem cell source | |||
| Bone marrow | 42 (73.7) | 7 (70) | |
| PBCS | 11 (19.3) | 3 (30) | 0.55 |
| Cord blood | 4 (7) | 0 | |
| Conditioning therapy | |||
| Myeloablative | 34 (59.6) | 8 (80) | 0.3 |
| Reduced intensity | 23 (40.4) | 2 (20) | |
| Engraftment, days | 20.5 (15–26) | 26 (13–48) | 0.41 |
| HSCT-related complications | |||
| Acute GVHD before day 100 | 8 (14.1) | 5 (50) | 0.019 |
| GVHD before day 28 | 3 (5.3) | 2 (20) | 0.16 |
| Viral infection before day 100 | 27 (46.6) | 6 (60) | 0.5 |
| Viral infection before day 28 | 8 (14) | 2 (20) | 0.64 |
| None of the 2 | 25 (43.9) | 1 (10) | |
| GVHD or viral reactivation | 30 (52.6) | 7 (70) | 0.012 |
| GVHD and viral reactivation | 2 (3.5) | 2 (20) | |
| Relapse-related mortality | 10 (17.5) | 0 | 0.34 |
| TRM | 7 (12.3) | 2 (20) | 0.28 |
Data presented are n (%) unless otherwise indicated.
PBSC, peripheral blood stem cell; IQR, interquartile range.